Search results for " Osteonecrosis of the jaw"

showing 10 items of 85 documents

Intravenous bisphosphonate-related osteonecrosis of the jaws: Influence of coadjuvant antineoplastic treatment and study of buccodental condition

2012

Objectives: To determine whether coadjuvant antineoplastic treatment can influence the number and size of bone exposures among patients with intravenous bisphosphonate-related osteonecrosis of the jaws (iBRONJ), and to analyze the buccodental condition of these patients. Material and methods: The study sample comprised 67 patients with iBRONJ, 53 patients without iBRONJ receiving treatment with intravenous bisphosphonates, and 36 healthy subjects. In all three groups, measurements were made of the CAO index and of resting whole saliva and stimulated whole saliva. In the patients with iBRONJ, the size (cm) and number of bone exposures were recorded. The data obtained were subjected to analys…

MaleMultivariate statisticsmedicine.medical_treatmentDentistryOdontologíaAntineoplastic AgentsLogistic regressionIntravenous bisphosphonatesmedicineHumansWhole salivaGeneral DentistryBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyDiphosphonatesbusiness.industryHealthy subjectsBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologyChemotherapy AdjuvantUNESCO::CIENCIAS MÉDICASInjections IntravenousSurgeryResearch-ArticleBisphosphonate-Associated Osteonecrosis of the JawFemaleAnalysis of variancebusinessMouth DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw

2017

Background Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence of exposed bone in the oral cavity that persists for more than eight weeks. Previous attempts to establish an animal model have not sufficiently considered disease features. Our aim was to establish an inexpensive and replicable animal model that develops BRONJ in a short time. Material and Methods Thirty-two male Wistar rats were randomly divided into two groups: control and experimental. In the experimental group, we administered 0.06mg/kg intraperitoneal dose of zoledronic acid (ZA) 7 and 14 days prior to maxillary second molar extraction. At two, four and six weeks after tooth …

MalePathologymedicine.medical_specialtymedicine.medical_treatmentMaxillary second molarH&E stainZoledronic AcidSequestrumRandom Allocation03 medical and health sciencesPostoperative Complications0302 clinical medicineTrichromemedicineAnimalsRats WistarGeneral DentistryOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchImidazoles030206 dentistry030224 pathologymedicine.disease:CIENCIAS MÉDICAS [UNESCO]RatsDisease Models AnimalZoledronic acidOtorhinolaryngologyDental extractionMaxillaTooth ExtractionUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgeryOsteonecrosis of the jawbusinessmedicine.drug
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct

Bisphosphonate-related osteonecrosis of the jaws (Bronj).

2011

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is an extremely therapy resistant osteomyelitis-like disease exclusively involving the jaw bones of patients in treatment with bisphosphonates (BPs). Objectives: The aim of this study was to evaluate the radiological and clinical findings and management of 51 patients with BRONJ diagnosed from 2004 to 2009 in our Reference Center. Study Design: A prospective study was performed. The patients were examined every 2-6 months, depending on their clinical conditions. Outcome variables were the resolution of symptoms, persistence of bone exposure and / or fistula and the status of the lesional mucosa. Results: The higher prevalence of the d…

Malemedicine.medical_specialtyFistulamedicine.medical_treatmentOdontologíaOsteotomySequestrummedicineHumansProspective StudiesProspective cohort studyGeneral DentistryPathologicalAgedBisphosphonate-associated osteonecrosis of the jawOral Medicine and Pathologybusiness.industryBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludCurettageSurgeryOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticlebusinessFollow-Up StudiesMedicina oral, patologia oral y cirugia bucal
researchProduct

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid…

2017

Background The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. Material and Methods This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. Results Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program af…

Malemedicine.medical_specialtyLongitudinal studyTime FactorsBone NeoplasmsZoledronic Acid03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsmedicineHumansIn patientLongitudinal StudiesGeneral DentistryAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ResearchIncidenceImidazolesRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryBone Density Conservation Agentsstomatognathic diseasesZoledronic acidOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain

2011

Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain. Study Design:A retrospective multicentre study was undertaken in 3 hospitals in an area with a radius less than 100 km in the Autonomous Community of Galicia (Spain). The medical records were reviewed and an oral examination was performed of patients diagnosed with oral bisphosphonate-related ONJ in the previous 3 years. Results: We detected 20 cases of ONJ (24 lesions) related to oral bisphosphonates (alendronate [16 patients] and ibandronate [4 patients]), which were mainly…

Malemedicine.medical_specialtyOsteoporosisCorticosteroid treatmentDiabetes mellitusmedicineHumansStage (cooking)Ibandronic AcidGeneral DentistryAgedRetrospective StudiesAged 80 and overSeries (stratigraphy)Oral Medicine and PathologyOral bisphosphonatesAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryMedical recordMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASOral examinationBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network …

2020

Background Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network (“Rete Oncologica Piemonte e Valle d’Aosta”), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants. Material and Methods MRONJ cases were collected retrospectively from January 2009 to June 2015; from July 2015 to December 2018, data were collected prospectively. Number of new MRONJ cas…

Malemedicine.medical_specialtyPopulation03 medical and health sciencescheek refinement0302 clinical medicineBreast cancerplasticInternal medicinemedicineCarcinomaHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective Studiesbuccal fat padeducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchIncidence (epidemiology)Cancer030206 dentistrymedicine.diseaseDenosumabZoledronic acidItalyOtorhinolaryngologyaestheticsfacial silhouette refiningbuccal fat pad excisionBisphosphonate-Associated Osteonecrosis of the JawSurgeryMultiple MyelomaOsteonecrosis of the jawbusinessmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Interleukin‐6 concentration changes in plasma and saliva in bisphosphonate‐related osteonecrosis of the jaws

2013

To determine the plasma and saliva levels of IL-6 in patients with bisphosphonate-related osteonecrosis of the jaws (BRONJ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL-6.We studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (ivBP), group 2 consisted of 25 patients treated with ivBP but without BRONJ, and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL-6 samples using an ELISA test.Significantly, higher IL-6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 (P  0.01). Group 1 showed no differences in plasma or saliva IL-…

Malemedicine.medical_specialtySalivamedicine.medical_treatmentDentistryGastroenterologyInternal medicinemedicineHumansIn patientStage (cooking)SalivaInterleukin 6General DentistryAgedDiphosphonatesbiologyInterleukin-6business.industryAdvanced stageBisphosphonateOtorhinolaryngologyElisa testbiology.proteinEtiologyBisphosphonate-Associated Osteonecrosis of the JawFemalebusinessOral Diseases
researchProduct

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct